查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1922400

日本溃疡性大肠炎市场报告：按类型、疾病类型、分子类型、药物类型、给药途径、分销管道和地区划分（2026-2034年）

Japan Ulcerative Colitis Market Report by Type, Disease Type, Molecule Type, Drug Type, Route of Administration, Distribution Channel, and Region 2026-2034
出版日期: | 出版商: IMARC | 英文 119 Pages | 商品交期: 5-7个工作天内

价格
简介目录

2025年，日本溃疡性大肠炎市场规模达3.638亿美元。 IMARC集团预测，到2034年，该市场规模将达到5.682亿美元，2026年至2034年的复合年增长率（CAGR）为5.08%。推动市场成长的主要因素包括日本溃疡性大肠炎发病率的上升、医疗基础设施的扩建和先进医疗技术的进步、研发活动的活性化、技术创新的加速以及医疗机构和患者支持团体加强宣传活动。

溃疡性大肠炎是一种发炎性肠道疾病，会损害大肠和直肠的内壁。症状包括持续性腹泻、直肠出血、腹痛、疲劳和体重减轻。溃疡性大肠炎被认为是由环境因素、遗传易感性和免疫反应过度共同作用引起的。诊断需要进行多项检查，包括粪便检验、血液检查、大肠镜检查和影像学检查。溃疡性大肠炎的治疗方法包括抗发炎药物、免疫抑制剂，以及在严重病例中可能需要手术治疗。这些治疗方法具有许多益处，包括缓解症状、降低復发率、减少大肠直肠癌等併发症的风险。它们还能改善营养吸收和消化功能，进而提升患者的整体生活品质。此外，这些治疗方法均有严谨的科学研究支持，能为患者带来显着的益处，包括长期缓解和减少住院需求。

日本溃疡性大肠炎市场趋势：

日本溃疡性大肠炎盛行率的不断上升是推动市场成长的主要因素之一。此外，高品质的医疗基础设施和先进的医疗技术使得疾病的精准诊断和有效治疗成为可能，为市场成长提供了广阔前景。同时，在政府津贴和政策支持下，製药业专注于新药和新治疗方法的研发，也促进了市场成长。此外，人工智慧（AI）等技术在诊断程序和数据分析中的应用，使得医疗服务提供者能够制定个人化的治疗方案，进一步推动了市场成长。远距远端医疗平台的日益普及，使得病患与医师之间的互动更加频繁且便捷，也进一步促进了市场成长。此外，医疗机构和病患权益组织所活性化的宣传活动，可望提高民众对溃疡性结肠炎的认知，促进早期诊断，进而进一步推动市场成长。最后，日本人口老化加剧导致溃疡性大肠炎发生率上升，也刺激了市场成长。此外，製药公司与学术机构之间日益密切的合作正在推动药物研发领域的创新，这对市场成长也产生了积极影响。因此，疗效显着、副作用更少、缓解期更长、住院次数更少的新型生物製药的推出，正在推动市场成长。此外，各公司日益重视旨在改善长期治疗效果的病患教育和依从性项目，也为国内市场带来了丰厚的成长机会。

本报告解答的关键问题

  • 日本溃疡性大肠炎市场目前发展如何？您认为未来几年它将如何发展？
  • COVID-19 对日本溃疡性大肠炎市场有何影响？
  • 日本溃疡性大肠炎市场按类型分類的情况如何？
  • 日本溃疡性大肠炎市场按疾病类型分類的市场区隔如何？
  • 日本溃疡性大肠炎市场按分子类型分類的市场组成是什么？
  • 日本溃疡性大肠炎市场按药物类型分類的市场组成是什么？
  • 日本溃疡性大肠炎市场如何根据给药途径进行细分？
  • 日本溃疡性大肠炎市场按分销管道分類的组成是怎样的？
  • 日本溃疡性大肠炎市场价值链的各个阶段有哪些？
  • 日本溃疡性大肠炎市场的主要驱动因素和挑战是什么？
  • 日本溃疡性大肠炎市场的结构是怎么样的？主要参与者有哪些？
  • 日本溃疡性大肠炎市场的竞争程度如何？

目录

第一章：序言

第二章：调查范围与调查方法

  • 调查目标
  • 相关利益者
  • 数据来源
  • 市场估值
  • 调查方法

第三章执行摘要

第四章 日本溃疡性大肠炎市场－引言

  • 概述
  • 市场动态
  • 产业趋势
  • 竞争资讯

第五章 日本溃疡性大肠炎市场概览

  • 过去和当前的市场趋势（2020-2025）
  • 市场预测（2026-2034）

第六章 日本溃疡性大肠炎市场－按类型细分

  • 轻度溃疡性大肠炎
  • 中度溃疡性大肠炎
  • 重度溃疡性大肠炎

第七章 日本溃疡性大肠炎市场－依疾病类型细分

  • 溃疡性直肠炎
  • 直肠乙状结肠炎
  • 左侧结肠炎
  • 全结肠炎或全结肠炎
  • 暴发性结肠炎

第八章：日本溃疡性大肠炎市场－依分子类型细分

  • 低分子化合物
  • 生物製药

第九章 日本溃疡性大肠炎市场－依药物类型细分

  • 抗发炎药
  • 抗TNF生物製药
  • 免疫抑制剂
  • Calcineurin抑制剂
  • 其他的

第十章 日本溃疡性大肠炎市场－依给药途径划分

  • 口服
  • 注射

第十一章 日本溃疡性大肠炎市场－依销售管道划分

  • 医院药房
  • 零售药房
  • 药局
  • 其他的

第十二章 日本溃疡性大肠炎市场－按地区划分

  • 关东地区
  • 关西、近畿地区
  • 中部地区
  • 九州和冲绳地区
  • 东北部地区
  • 中国地区
  • 北海道地区
  • 四国地区

第十三章：日本溃疡性大肠炎市场：竞争格局

  • 概述
  • 市场结构
  • 市场公司定位
  • 关键成功策略
  • 竞争对手仪錶板
  • 企业估值象限

第十四章主要企业简介

第十五章 日本溃疡性大肠炎市场：产业分析

  • 驱动因素、限制因素和机会
  • 波特五力分析
  • 价值链分析

第十六章附录

简介目录
Product Code: SR112026A19356

The Japan ulcerative colitis market size reached USD 363.8 Million in 2025 . Looking forward, IMARC Group expects the market to reach USD 568.2 Million by 2034 , exhibiting a growth rate (CAGR) of 5.08% during 2026-2034 . The increasing prevalence of ulcerative colitis in Japan, rising healthcare infrastructure and advanced medical technologies, growing research and development (R&D) initiatives, rapid technological advancements, and heightened public awareness initiatives by healthcare organizations and patient advocacy groups represent some of the key factors driving the market.

Access the full market insights report Request Sample

Ulcerative colitis refers to an inflammatory bowel disease that adversely affects the lining of the large intestine and rectum. It exhibits various symptoms, such as persistent diarrhea, rectal bleeding, abdominal pain, fatigue, and weight loss. Ulcerative colitis is suspected to be caused by a combination of environmental factors, genetic predisposition, and an overactive immune response. It is diagnosed through multiple tests, such as stool samples, blood tests, colonoscopy, and imaging studies. Ulcerative colitis is treated using anti-inflammatory medications, immunosuppressants, and, in more severe cases, surgical intervention. The treatments offer numerous benefits, including symptom relief, decreased frequency of flare-ups, and reduced risk of complications, such as colon cancer. They also improve the overall quality of life for patients by enabling better nutrient absorption and digestive function. Moreover, the therapies, backed by rigorous scientific research, provide patients with substantial advantages, such as long-lasting remission periods and a decreased need for hospitalization.

JAPAN ULCERATIVE COLITIS MARKET TRENDS:

The increasing prevalence of ulcerative colitis in Japan is one of the major factors contributing to the market growth. Moreover, the presence of a high-quality healthcare infrastructure and advanced medical technologies, allowing for precise diagnosis and effective management of the disease, is creating a positive outlook for the market growth. Additionally, the growing focus of the pharmaceutical industry on research and development (R&D) of new drugs and therapies, aided by government support in the form of grants and policies, is supporting the market growth. Along with this, rapid technological advancements, such as the integration of artificial intelligence (AI) in diagnostic procedures and data analytics, enabling healthcare providers to develop personalized treatment plans, are enhancing the market growth. In addition to this, the increasing adoption of telemedicine platforms, allowing for more frequent and convenient patient-doctor interactions, is bolstering the market growth. Besides this, the rising public awareness initiatives by healthcare organizations and patient advocacy groups, raising the profile of the disease and leading to earlier diagnosis, are anticipated to drive the market growth. Apart from this, the growing geriatric population in Japan, resulting in heightened incidences of ulcerative colitis, is also stimulating the market growth. Furthermore, the rising partnerships between pharmaceutical companies and academic institutions, fostering innovation in drug development and research, are positively influencing the market growth. In line with this, the introduction of new biologic drugs, offering effective results, fewer side effects, longer remission periods, and reduced hospital visits, are providing a thrust to the market growth. Moreover, the increasing focus by companies on patient education and compliance programs to improve long-term treatment outcomes is offering lucrative growth opportunities for the market across the country.

JAPAN ULCERATIVE COLITIS MARKET SEGMENTATION:

Type Insights:

  • To get detailed segment analysis of this market Request Sample
  • Mild UC
  • Moderate UC
  • Severe UC
  • Mild UC
  • Moderate UC
  • Severe UC

Disease Type Insights:

  • Ulcerative Proctitis
  • Proctosigmoiditis
  • Left-sided Colitis
  • Pancolitis or Universal Colitis
  • Fulminant Colitis
  • Ulcerative Proctitis
  • Proctosigmoiditis
  • Left-sided Colitis
  • Pancolitis or Universal Colitis
  • Fulminant Colitis

Molecule Type Insights:

  • Small Molecules
  • Biologics
  • Small Molecules
  • Biologics

Drug Type Insights:

  • Anti-Inflammatory Drugs
  • Anti-TNF Biologics
  • Immunosuppressant
  • Calcineurin Inhibitors
  • Others
  • Anti-Inflammatory Drugs
  • Anti-TNF Biologics
  • Immunosuppressant
  • Calcineurin Inhibitors
  • Others

Route of Administration Insights:

  • Oral
  • Injectable
  • Oral
  • Injectable

Distribution Channel Insights:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Store
  • Others
  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Store
  • Others

Regional Insights:

  • To get detailed regional analysis of this market Request Sample
  • Kanto Region
  • Kansai/Kinki Region
  • Central/ Chubu Region
  • Kyushu-Okinawa Region
  • Tohoku Region
  • Chugoku Region
  • Hokkaido Region
  • Shikoku Region
  • Kanto Region
  • Kansai/Kinki Region
  • Central/ Chubu Region
  • Kyushu-Okinawa Region
  • Tohoku Region
  • Chugoku Region
  • Hokkaido Region
  • Shikoku Region
  • The report has also provided a comprehensive analysis of all the major regional markets, which include Kanto Region, Kansai/Kinki Region, Central/ Chubu Region, Kyushu-Okinawa Region, Tohoku Region, Chugoku Region, Hokkaido Region, and Shikoku Region.

COMPETITIVE LANDSCAPE:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

  • KEY QUESTIONS ANSWERED IN THIS REPORT
  • How has the Japan ulcerative colitis market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the Japan ulcerative colitis market?
  • What is the breakup of the Japan ulcerative colitis market on the basis of type?
  • What is the breakup of the Japan ulcerative colitis market on the basis of disease type?
  • What is the breakup of the Japan ulcerative colitis market on the basis of molecule type?
  • What is the breakup of the Japan ulcerative colitis market on the basis of drug type?
  • What is the breakup of the Japan ulcerative colitis market on the basis of route of administration?
  • What is the breakup of the Japan ulcerative colitis market on the basis of distribution channel?
  • What are the various stages in the value chain of the Japan ulcerative colitis market?
  • What are the key driving factors and challenges in the Japan ulcerative colitis?
  • What is the structure of the Japan ulcerative colitis market and who are the key players?
  • What is the degree of competition in the Japan ulcerative colitis market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Japan Ulcerative Colitis Market - Introduction

  • 4.1 Overview
  • 4.2 Market Dynamics
  • 4.3 Industry Trends
  • 4.4 Competitive Intelligence

5 Japan Ulcerative Colitis Market Landscape

  • 5.1 Historical and Current Market Trends (2020-2025)
  • 5.2 Market Forecast (2026-2034)

6 Japan Ulcerative Colitis Market - Breakup by Type

  • 6.1 Mild UC
    • 6.1.1 Overview
    • 6.1.2 Historical and Current Market Trends (2020-2025)
    • 6.1.3 Market Forecast (2026-2034)
  • 6.2 Moderate UC
    • 6.2.1 Overview
    • 6.2.2 Historical and Current Market Trends (2020-2025)
    • 6.2.3 Market Forecast (2026-2034)
  • 6.3 Severe UC
    • 6.3.1 Overview
    • 6.3.2 Historical and Current Market Trends (2020-2025)
    • 6.3.3 Market Forecast (2026-2034)

7 Japan Ulcerative Colitis Market - Breakup by Disease Type

  • 7.1 Ulcerative Proctitis
    • 7.1.1 Overview
    • 7.1.2 Historical and Current Market Trends (2020-2025)
    • 7.1.3 Market Forecast (2026-2034)
  • 7.2 Proctosigmoiditis
    • 7.2.1 Overview
    • 7.2.2 Historical and Current Market Trends (2020-2025)
    • 7.2.3 Market Forecast (2026-2034)
  • 7.3 Left-sided Colitis
    • 7.3.1 Overview
    • 7.3.2 Historical and Current Market Trends (2020-2025)
    • 7.3.3 Market Forecast (2026-2034)
  • 7.4 Pancolitis or Universal Colitis
    • 7.4.1 Overview
    • 7.4.2 Historical and Current Market Trends (2020-2025)
    • 7.4.3 Market Forecast (2026-2034)
  • 7.5 Fulminant Colitis
    • 7.5.1 Overview
    • 7.5.2 Historical and Current Market Trends (2020-2025)
    • 7.5.3 Market Forecast (2026-2034)

8 Japan Ulcerative Colitis Market - Breakup by Molecule Type

  • 8.1 Small Molecules
    • 8.1.1 Overview
    • 8.1.2 Historical and Current Market Trends (2020-2025)
    • 8.1.3 Market Forecast (2026-2034)
  • 8.2 Biologics
    • 8.2.1 Overview
    • 8.2.2 Historical and Current Market Trends (2020-2025)
    • 8.2.3 Market Forecast (2026-2034)

9 Japan Ulcerative Colitis Market - Breakup by Drug Type

  • 9.1 Anti-Inflammatory Drugs
    • 9.1.1 Overview
    • 9.1.2 Historical and Current Market Trends (2020-2025)
    • 9.1.3 Market Forecast (2026-2034)
  • 9.2 Anti-TNF Biologics
    • 9.2.1 Overview
    • 9.2.2 Historical and Current Market Trends (2020-2025)
    • 9.2.3 Market Forecast (2026-2034)
  • 9.3 Immunosuppressant
    • 9.3.1 Overview
    • 9.3.2 Historical and Current Market Trends (2020-2025)
    • 9.3.3 Market Forecast (2026-2034)
  • 9.4 Calcineurin Inhibitors
    • 9.4.1 Overview
    • 9.4.2 Historical and Current Market Trends (2020-2025)
    • 9.4.3 Market Forecast (2026-2034)
  • 9.5 Others
    • 9.5.1 Historical and Current Market Trends (2020-2025)
    • 9.5.2 Market Forecast (2026-2034)

10 Japan Ulcerative Colitis Market - Breakup by Route of Administration

  • 10.1 Oral
    • 10.1.1 Overview
    • 10.1.2 Historical and Current Market Trends (2020-2025)
    • 10.1.3 Market Forecast (2026-2034)
  • 10.2 Injectable
    • 10.2.1 Overview
    • 10.2.2 Historical and Current Market Trends (2020-2025)
    • 10.2.3 Market Forecast (2026-2034)

11 Japan Ulcerative Colitis Market - Breakup by Distribution Channel

  • 11.1 Hospital Pharmacies
    • 11.1.1 Overview
    • 11.1.2 Historical and Current Market Trends (2020-2025)
    • 11.1.3 Market Forecast (2026-2034)
  • 11.2 Retail Pharmacies
    • 11.2.1 Overview
    • 11.2.2 Historical and Current Market Trends (2020-2025)
    • 11.2.3 Market Forecast (2026-2034)
  • 11.3 Drug Store
    • 11.3.1 Overview
    • 11.3.2 Historical and Current Market Trends (2020-2025)
    • 11.3.3 Market Forecast (2026-2034)
  • 11.4 Others
    • 11.4.1 Historical and Current Market Trends (2020-2025)
    • 11.4.2 Market Forecast (2026-2034)

12 Japan Ulcerative Colitis Market - Breakup by Region

  • 12.1 Kanto Region
    • 12.1.1 Overview
    • 12.1.2 Historical and Current Market Trends (2020-2025)
    • 12.1.3 Market Breakup by Type
    • 12.1.4 Market Breakup by Disease Type
    • 12.1.5 Market Breakup by Molecule Type
    • 12.1.6 Market Breakup by Drug Type
    • 12.1.7 Market Breakup by Route of Administration
    • 12.1.8 Market Breakup by Distribution Channel
    • 12.1.9 Key Players
    • 12.1.10 Market Forecast (2026-2034)
  • 12.2 Kansai/Kinki Region
    • 12.2.1 Overview
    • 12.2.2 Historical and Current Market Trends (2020-2025)
    • 12.2.3 Market Breakup by Type
    • 12.2.4 Market Breakup by Disease Type
    • 12.2.5 Market Breakup by Molecule Type
    • 12.2.6 Market Breakup by Drug Type
    • 12.2.7 Market Breakup by Route of Administration
    • 12.2.8 Market Breakup by Distribution Channel
    • 12.2.9 Key Players
    • 12.2.10 Market Forecast (2026-2034)
  • 12.3 Central/ Chubu Region
    • 12.3.1 Overview
    • 12.3.2 Historical and Current Market Trends (2020-2025)
    • 12.3.3 Market Breakup by Type
    • 12.3.4 Market Breakup by Disease Type
    • 12.3.5 Market Breakup by Molecule Type
    • 12.3.6 Market Breakup by Drug Type
    • 12.3.7 Market Breakup by Route of Administration
    • 12.3.8 Market Breakup by Distribution Channel
    • 12.3.9 Key Players
    • 12.3.10 Market Forecast (2026-2034)
  • 12.4 Kyushu-Okinawa Region
    • 12.4.1 Overview
    • 12.4.2 Historical and Current Market Trends (2020-2025)
    • 12.4.3 Market Breakup by Type
    • 12.4.4 Market Breakup by Disease Type
    • 12.4.5 Market Breakup by Molecule Type
    • 12.4.6 Market Breakup by Drug Type
    • 12.4.7 Market Breakup by Route of Administration
    • 12.4.8 Market Breakup by Distribution Channel
    • 12.4.9 Key Players
    • 12.4.10 Market Forecast (2026-2034)
  • 12.5 Tohoku Region
    • 12.5.1 Overview
    • 12.5.2 Historical and Current Market Trends (2020-2025)
    • 12.5.3 Market Breakup by Type
    • 12.5.4 Market Breakup by Disease Type
    • 12.5.5 Market Breakup by Molecule Type
    • 12.5.6 Market Breakup by Drug Type
    • 12.5.7 Market Breakup by Route of Administration
    • 12.5.8 Market Breakup by Distribution Channel
    • 12.5.9 Key Players
    • 12.5.10 Market Forecast (2026-2034)
  • 12.6 Chugoku Region
    • 12.6.1 Overview
    • 12.6.2 Historical and Current Market Trends (2020-2025)
    • 12.6.3 Market Breakup by Type
    • 12.6.4 Market Breakup by Disease Type
    • 12.6.5 Market Breakup by Molecule Type
    • 12.6.6 Market Breakup by Drug Type
    • 12.6.7 Market Breakup by Route of Administration
    • 12.6.8 Market Breakup by Distribution Channel
    • 12.6.9 Key Players
    • 12.6.10 Market Forecast (2026-2034)
  • 12.7 Hokkaido Region
    • 12.7.1 Overview
    • 12.7.2 Historical and Current Market Trends (2020-2025)
    • 12.7.3 Market Breakup by Type
    • 12.7.4 Market Breakup by Disease Type
    • 12.7.5 Market Breakup by Molecule Type
    • 12.7.6 Market Breakup by Drug Type
    • 12.7.7 Market Breakup by Route of Administration
    • 12.7.8 Market Breakup by Distribution Channel
    • 12.7.9 Key Players
    • 12.7.10 Market Forecast (2026-2034)
  • 12.8 Shikoku Region
    • 12.8.1 Overview
    • 12.8.2 Historical and Current Market Trends (2020-2025)
    • 12.8.3 Market Breakup by Type
    • 12.8.4 Market Breakup by Disease Type
    • 12.8.5 Market Breakup by Molecule Type
    • 12.8.6 Market Breakup by Drug Type
    • 12.8.7 Market Breakup by Route of Administration
    • 12.8.8 Market Breakup by Distribution Channel
    • 12.8.9 Key Players
    • 12.8.10 Market Forecast (2026-2034)

13 Japan Ulcerative Colitis Market - Competitive Landscape

  • 13.1 Overview
  • 13.2 Market Structure
  • 13.3 Market Player Positioning
  • 13.4 Top Winning Strategies
  • 13.5 Competitive Dashboard
  • 13.6 Company Evaluation Quadrant

14 Profiles of Key Players

  • 14.1 Company A
    • 14.1.1 Business Overview
    • 14.1.2 Services Offered
    • 14.1.3 Business Strategies
    • 14.1.4 SWOT Analysis
    • 14.1.5 Major News and Events
  • 14.2 Company B
    • 14.2.1 Business Overview
    • 14.2.2 Services Offered
    • 14.2.3 Business Strategies
    • 14.2.4 SWOT Analysis
    • 14.2.5 Major News and Events
  • 14.3 Company C
    • 14.3.1 Business Overview
    • 14.3.2 Services Offered
    • 14.3.3 Business Strategies
    • 14.3.4 SWOT Analysis
    • 14.3.5 Major News and Events
  • 14.4 Company D
    • 14.4.1 Business Overview
    • 14.4.2 Services Offered
    • 14.4.3 Business Strategies
    • 14.4.4 SWOT Analysis
    • 14.4.5 Major News and Events
  • 14.5 Company E
    • 14.5.1 Business Overview
    • 14.5.2 Services Offered
    • 14.5.3 Business Strategies
    • 14.5.4 SWOT Analysis
    • 14.5.5 Major News and Events

15 Japan Ulcerative Colitis Market - Industry Analysis

  • 15.1 Drivers, Restraints, and Opportunities
    • 15.1.1 Overview
    • 15.1.2 Drivers
    • 15.1.3 Restraints
    • 15.1.4 Opportunities
  • 15.2 Porters Five Forces Analysis
    • 15.2.1 Overview
    • 15.2.2 Bargaining Power of Buyers
    • 15.2.3 Bargaining Power of Suppliers
    • 15.2.4 Degree of Competition
    • 15.2.5 Threat of New Entrants
    • 15.2.6 Threat of Substitutes
  • 15.3 Value Chain Analysis

16 Appendix